PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378605
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1378605
Global Urinary Incontinence Treatment Drugs Market is estimated to be valued at US$ 4.41 Bn in 2023, and is expected to exhibit a CAGR of 3.4% during the forecast period (2023-2030).
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 4.41 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 3.40% | 2030 Value Projection: | US$ 5.56 Bn |
Urinary incontinence means losing control of bladder that leads to involuntary leakage of urine. In this condition, control over the urinary sphincter is weakened or completely lost, and thus, a person urinates even when they do not want to. This is a very common and often embarrassing problem for people. At the time of urination, muscles around urethra relax and let urine pass out of the body, however, in urinary incontinence, muscles around urethra do not work in the way they should, and resulting in leak of urine. Urinary incontinence can be caused by everyday habits, underlying medical conditions, or physical problems. There are various type of incontinences such as stress (bladder is under pressure), urge (intense urge to pass urine), and overflow (chronic urinary retention). The severity of urinary incontinence varies as per the health conditions such as urinary tract infection (UTI), constipation, and urinary incontinence . Urinary incontinence is found more in geriatric population.
Key players in the market are focusing on the development of cost efficient solutions. Thus, introduction of new and advanced products in the market is expected to drive growth of the global urinary incontinence treatment drugs market over the forecast period. For instance, on March 15, 2023, MSN Laboratories, a leading pharmaceutical company, announced the launch of Fesobig, the world's first bioequivalent generic version of fesoterodine fumarate. Fesobig is recommended by various international treatment guidelines for the treatment of overactive bladder (OAB) and urinary incontinence (UI), as the safest and novel first-line pharmacotherapy option. The company have ensured that the drug has an affordable price so that it can benefit a large majority of patients. As overactive bladder (OAB) is an involuntary loss of urine due to pelvic floor dysfunction, which is strongly associated with the female population. The prevalence of urinary incontinence in India is also relatively high, ranging from 10% in rural areas to 34% in urban areas. Although urinary incontinence is not a life-threatening condition, it causes discomfort, embarrassment and a loss of self-confidence.
Global Urinary Incontinence Treatment Drugs Market Detailed Segmentation: